Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07272057

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

The goal of this clinical trial

The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:

* Does adding an SGLT2 inhibitor to standard cancer treatment improve survival? * Does it cause more or fewer cardiovascular toxicity? * What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.

Participants will:

* Be adults diagnosed with advanced lung cancer and type 2 diabetes. * Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment. * Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Lung cancer patients receiving standard anti-tumor treatment; type 2 diabetes; patients with a score of 0-2 assessed by Eastern Cooperative Oncology Group's performance status; the patients agreed to participate in this study.

Exclusion criteria

  • Severe abnormalities in liver, kidney or heart functions; expected lifespan less than 3 months.

Treatment and study plan

SGLT-2 inhibitor

Drug

SGLT2 inhibitors used for patients with lung cancer and diabetes

Sham (No Treatment)

Other

SGLT2 inhibitors are not used for patients with lung cancer and diabetes

Primary outcomes

  1. Number of Participants with death

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. Number of Participants with new-onset atrial fibrillation/flutter, acute coronary syndrome, myocarditis, massive pericardial effusion, heart failure and third-degree atrioventricular block.

    Time frame: From enrollment to the end of treatment at 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Jindong Chen

CONTACT

[email protected]

+862122200000

Sponsors and collaborators

Lead sponsor

Shanghai Chest Hospital

Other

Registry information

Official study title

The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 9, 2025
Registry last updated
Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.